Theravectys, a Paris, France-based biotech company specialized in the development of a new generation of therapeutic vaccines and immunotherapies against major global infectious diseases and cancers, received a €1.9m grant from Bpifrance.
The funding was provided in the form of a repayable advance as part of the Development of Innovation Assistance program (ADI).
The company will use the sum to conduct the preclinical and Phase I/II trials related to its first vaccine candidate in oncology and against an indication of particular interest for Japan
Led by Renaud Vaillant, Chief Executive Officer, Theravectys is a discovery and clinical development biotech company originating from the Pasteur Institute which capitalizes over 15 years of fundamental research in the field of lentiviral vectors and has secured worldwide exclusive rights to Pasteur Institute intellectual property.
Based on its lentiviral vector technology platform, Theravectys develops therapeutic vaccines and immunotherapies to fight cancers and infectious diseases, including a proprietary and differentiated CAR T-cell technology platform.